ArticlePloS one2013
Bacteriophage receptor binding protein based assays for the simultaneous detection of Campylobacter jejuni and Campylobacter coli.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 55 citations in OpenAlex.
- Phage receptor binding protein and Fc fragment fusion enhances phagocytosis of Y. enterocolitica.AMB Express · 2025Article
- Phage-derived proteins: Advancing food safety through biocontrol and detection of foodborne pathogens.Comprehensive reviews in food science and food safety · 2025Review
- A Bacteriophage Protein-Based Impedimetric Electrochemical Biosensor for the Detection ofBiosensors · 2024Article
- Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.Journal of clinical laboratory analysis · 2023Review
- Bacteriophage Tail Proteins as a Tool for Bacterial Pathogen Recognition-A Literature Review.Antibiotics (Basel, Switzerland) · 2022Review
- A Phage Receptor-Binding Protein as a Promising Tool for the Detection ofFrontiers in microbiology · 2022Article
- The Age of Phage: Friend or Foe in the New Dawn of Therapeutic and Biocontrol Applications?Pharmaceuticals (Basel, Switzerland) · 2021Review
- Opportunities and Challenges of Bacterial Glycosylation for the Development of Novel Antibacterial Strategies.Frontiers in microbiology · 2021Review
- Bacteriophage Usage for Bacterial Disease Management and Diagnosis in Plants.The plant pathology journal · 2020Review
- Binding of Phage-Encoded FlaGrab to MotileFrontiers in microbiology · 2020Article
- Understanding and Exploiting Phage-Host Interactions.Viruses · 2019Review
- Complete Genome Sequence of Campylobacter jejuni Strain 12567, a Livestock-Associated Clade Representative.Genome announcements · 2018Article
- Review of the nature, diversity and structure of bacteriophage receptor binding proteins that target Gram-positive bacteria.Biophysical reviews · 2018Review
- Quantitative and synthetic biology approaches to combat bacterial pathogens.Current opinion in biomedical engineering · 2017Article
- Evaluation of lytic bacteriophages for control of multidrug-resistant Salmonella Typhimurium.Annals of clinical microbiology and antimicrobials · 2017Article
- Modified Bacteriophage S16 Long Tail Fiber Proteins for Rapid and Specific Immobilization and Detection of Salmonella Cells.Applied and environmental microbiology · 2017Article
- Yersinia enterocolitica-Specific Infection by Bacteriophages TG1 and ϕR1-RT Is Dependent on Temperature-Regulated Expression of the Phage Host Receptor OmpF.Applied and environmental microbiology · 2016Article
- Genetically Engineered Phages: a Review of Advances over the Last Decade.Microbiology and molecular biology reviews : MMBR · 2016Review
- Bacteriophage-based tools: recent advances and novel applications.F1000Research · 2016Review
- A Flagellar Glycan-Specific Protein Encoded by Campylobacter Phages Inhibits Host Cell Growth.Viruses · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Campylobacter jejuni and Campylobacter coli are the most common bacterial causes of foodborne gastroenteritis which is occasionally followed by a debilitating neuropathy known as Guillain-Barré syndrome. Rapid and specific detection of these pathogens is very important for effective control and quick treatment of infection. Most of the diagnostics available for these organisms are time consuming and require technical expertise with expensive instruments and reagents to perform. Bacteriophages bind to their host specifically through their receptor binding proteins (RBPs), which can be exploited for pathogen detection. We recently sequenced the genome of C. jejuni phage NCTC12673 and identified its putative host receptor binding protein, Gp047. In the current study, we localized the receptor binding domain to the C-terminal quarter of Gp047. CC-Gp047 could be produced recombinantly and was capable of agglutinating both C. jejuni and C. coli cells unlike the host range of the parent phage which is limited to a subset of C. jejuni isolates. The agglutination procedure could be performed within minutes on a glass slide at room temperature and was not hindered by the presence of buffers or nutrient media. This agglutination assay showed 100% specificity and the sensitivity was 95% for C. jejuni (n = 40) and 90% for C. coli (n = 19). CC-Gp047 was also expressed as a fusion with enhanced green fluorescent protein (EGFP). Chimeric EGFP_CC-Gp047 was able to specifically label C. jejuni and C. coli cells in mixed cultures allowing for the detection of these pathogens by fluorescent microscopy. This study describes a simple and rapid method for the detection of C. jejuni and C. coli using engineered phage RBPs and offers a promising new diagnostics platform for healthcare and surveillance laboratories.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.